Back to Journals » International Journal of Chronic Obstructive Pulmonary Disease » Volume 9 » Issue 1

Clinical benefit of fixed-dose dual bronchodilation with glycopyrronium and indacaterol once daily in patients with chronic obstructive pulmonary disease: a systematic review

Authors Ulrik CS

Received 9 January 2014

Accepted for publication 20 February 2014

Published 1 April 2014 Volume 2014:9(1) Pages 331—338


Checked for plagiarism Yes

Review by Single-blind

Peer reviewer comments 4

Charlotte Suppli Ulrik

Department of Respiratory Medicine, Hvidovre Hospital and University of Copenhagen, Hvidovre, Denmark

Background and aim: Long-acting bronchodilators are the preferred option for maintenance therapy of patients with chronic obstructive pulmonary disease (COPD). The aim of this review is to provide an overview of the clinical studies evaluating the clinical efficacy of the once-daily fixed-dose dual bronchodilator combination of indacaterol and glycopyrronium bromide in patients suffering from COPD.
Methods: This study comprised a systematic review of randomized controlled trials identified through systematic searches of different databases of published trials.
Results: Nine trials (6,166 participants) were included. Fixed-dose once-daily indacaterol/glycopyrronium seems to be safe and well tolerated in patients with COPD. Compared with single therapy with other long-acting bronchodilators (indacaterol, glycopyrronium, and tiotropium) and fixed-combination long-acting β2-agonist/inhaled corticosteroid (salmeterol/fluticasone twice daily), once-daily fixed-dose indacaterol/glycopyrronium has clinically important effects on symptoms, including dyspnea score, health status, level of lung function, and rate of moderate or severe exacerbations in patients with moderate-to-very severe COPD (Global initiative for chronic Obstructive Lung Disease [GOLD] spirometric criteria). Furthermore, a very recent study has shown that fixed-dose indacaterol/glycopyrronium improves exercise endurance time compared with placebo, although no significant difference was observed between fixed-dose indacaterol/glycopyrronium and tiotropium.
Conclusion: Fixed-dose indacaterol/glycopyrronium has clinically relevant effects on important COPD outcome measures and is, in general, superior to therapy with a single long-acting bronchodilator (with or without inhaled corticosteroid) indicating long-acting dual bronchodilation as a potential important maintenance therapeutic option for patients with symptomatic COPD, possibly also for the treatment of naïve patients.

Keywords: COPD, long-acting bronchodilators, glycopyrronium, indacaterol

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]


Other articles by this author:

Do telemedical interventions improve quality of life in patients with COPD? A systematic review

Gregersen TL, Green A, Frausing E, Ringbæk T, Brøndum E, Suppli Ulrik C

International Journal of Chronic Obstructive Pulmonary Disease 2016, 11:809-822

Published Date: 21 April 2016

Beta-blockers: friend or foe in asthma?

Arboe B, Ulrik CS

International Journal of General Medicine 2013, 6:549-555

Published Date: 8 July 2013

Long-term survival in patients hospitalized for chronic obstructive pulmonary disease: a prospective observational study in the Nordic countries

Gudmundsson G, Ulrik CS, Gislason T, Lindberg E, Brøndum E, Bakke P, Janson C

International Journal of Chronic Obstructive Pulmonary Disease 2012, 7:571-576

Published Date: 14 September 2012

Asthma and obesity: does weight loss improve asthma control? a systematic review

Juel CTB, Ali Z, Nilas L, Ulrik CS

Journal of Asthma and Allergy 2012, 5:21-26

Published Date: 7 June 2012

Early detection of COPD in general practice

Charlotte Suppli Ulrik, Anders Løkke, Ronald Dahl, et al

International Journal of Chronic Obstructive Pulmonary Disease 2011, 6:123-127

Published Date: 28 January 2011

Readers of this article also read:

Hematuria following Botox treatment for upper limb spasticity: a case report

Lo TC, Yeung ST, Lee S, Chang EY

Journal of Pain Research 2015, 8:619-622

Published Date: 14 September 2015

The concept of control of COPD in clinical practice

Soler-Cataluña JJ, Alcázar-Navarrete B, Miravitlles M

International Journal of Chronic Obstructive Pulmonary Disease 2014, 9:1397-1405

Published Date: 12 December 2014

Patient preference and ease of use for different coagulation factor VIII reconstitution device scenarios: a cross-sectional survey in five European countries

Cimino E, Linari S, Malerba M, Halimeh S, Biondo F, Westfeld M

Patient Preference and Adherence 2014, 8:1713-1720

Published Date: 12 December 2014

Characteristics of undiagnosed COPD in a senior community center

Santos SR, Lizzi ES, Vianna EO

International Journal of Chronic Obstructive Pulmonary Disease 2014, 9:1155-1161

Published Date: 15 October 2014

Corrigendum: Softec HD hydrophilic acrylic intraocular lens: biocompatibility and precision

Espandar L, Sikder S, Moshirfar M

Clinical Ophthalmology 2011, 5:159-160

Published Date: 6 February 2011

Crystallization after intravitreal ganciclovir injection

Pitipol Choopong, Nattaporn Tesavibul, Nattawut Rodanant

Clinical Ophthalmology 2010, 4:709-711

Published Date: 14 July 2010